Rat peritoneal mast cells release regulated upon activation normal T cell expressed and secreted (RANTES) after TNF-α activation

Journal of Biological Regulators and Homeostatic Agents

Volumn 19, Issue 3-4, 2005, Pages 130-135

  Kempuraj, D ^a   Petrarca, C ^b   Frydas, S ^c   Riccioni, G ^b   Conti, P ^b   Tete S ^b   Vecchiet, Jocopo ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHIETI   (Italy)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

LPS; Mast cell; RANTES; TNF

Indexed keywords

CALCIMYCIN; LIPOPOLYSACCHARIDE; MESSENGER RNA; RANTES; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CELL ACTIVATION; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; IN VIVO STUDY; INFLAMMATION; NONHUMAN; PERITONEUM MAST CELL; RAT; SUPERNATANT; ANIMAL; ASCITES FLUID; BIOSYNTHESIS; CYTOLOGY; DRUG EFFECT; ELECTRON MICROSCOPY; GENETICS; IMMUNOLOGY; IN VITRO STUDY; MALE; MAST CELL; METABOLISM; SPRAGUE DAWLEY RAT; ULTRASTRUCTURE;

RATTUS;

ANIMALS; ASCITIC FLUID; CALCIMYCIN; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MAST CELLS; MICROSCOPY, ELECTRON; RANTES; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33744510184     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Oppenheim JJ, Zacharie COC, Mukaida N, Matsushima K. Properties of the novel proinflammatory supergene "Intercrine" cytokine family. Ann Rev Immunol 1991; 9: 617-48.
2. Frydas S, Karagouni E, Hatzistilianou M, et al. Chemokines and allergic disorders: A revised study. Int J Immunopathol Pharmacol 2004; 17: 233-5.
3. Kempuraj D, Frydas S, Conti P, et al. Interleukin-25: A new IL-17 family member with growth factor/inflammatory action. Int J Immunopathol Pharmacol 2003; 16: 185-8.
4. Huang SH, Frydas S, Conti P, et al. Interleukin-17: A revisited study. Int J Immunopathol Pharmacol 2004; 17: 1-8.
5. Kempuraj D, Frydas S, Kandere K, et al. Interleukin-19 (IL-19) network revisited. Int J Immunopathol Pharmacol 2003; 16: 95-8.
6. Appert-Collin A, Duong FHT, Passilly Degrace P, Warter J-M, Poindron P, Gies J-P. MAPK activation via 5-hydroxytryptamine 1A receptor is involved in the neuroprotective effects of xaliproden. Int J Immunopathol Pharmacol 2005; 18: 21-32.
7. Baggiolini M Dahinden CA. CC chemokines in allergic inflammation. Immunol Today 1994; 15: 127-33.
8. Matsushima K, Morishita K, Yoshimura T, et al. Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin-1 and tumor necrosis factor. J Exp Med 1988; 167: 1883-93.
9. Trubiani O, Guarnieri S, Orciani M, Salvolini E, Di Primio R. Sphingolipid microdomains mediate CD38 internalization: Topography of the endocytosis. Int J Immunopathol Pharmacol 2004; 17: 293-300.
10. Frydas S, Hatzistilianou M, Karagouni E, et al. Chemokines and parasites. Int J Immunopathol Pharmacol 2003; 16: 221-4.
11. Cassano N, Loconsole F, Amoruso A, et al. Infliximab monotherapy for refractory psoriasis: Preliminary results. Int J Immunopathol Pharmacol 2004; 17: 373-80.
12. Roux ME, Marquez MG, Olmos S, Frecha-Florin CA Christensen A. Compartmentalisation between gut and lung mucosae in a model of secondary immunodeficiency. Effect of thymomodulin. Int J Immunopathol Pharmacol 2003; 16: 151-6.
13. Di Giannantonio M, Frydas S, Kempuraj D, et al. Cytokines in stress. Int J Immunopathol Pharmacol 2005; 18: 1-6.
14. Kempuraj D, Frydas S, Karagouni E, et al. Cytokines and the brain. Int J Immunopathol Pharmacol 2004; 17: 229-32.
15. Theoharides TC, Bondy PK, Tsakalos ND Askenase PW. Differential release of serotonin and histamine from mast cells. Nature 1982; 297: 229-31.
16. Sodin-Semrl S, Spagnolo A, Mikus R, Barbaro B, Varga J, Fiore S. Opposing regulation of interleukin-8 and NF-kappaB responses by lipoxin A4 and serum amyloid A via the common lipoxin A receptor. Int J Immunopathol Pharmacol 2004; 17: 145-56.
17. Theoharides TC, Sant GR. A pilot open label study of Cystoprotek® in interstitial cystitis. Int J Immunopathol Pharmacol 2005; 18: 183-8.
18. Frydas S, Papaioannou N, Papazahariadou M, et al. Inhibition of MCP-1 and MIP-2 chemokines in murine trichinellosis: Effect of the anti-inflammatory compound I-mimosine. Int J Immunopathol Pharmacol 2005; 18: 85-94.
19. Centurione L, Di Giulio C, Santavenere E, et al. Protein kinase C ζ regulation of hypertrophic and apoptotic events occurring during rat neonatal heart development and growth. Int J Immunopathol Pharmacol 2005; 18: 49-58.
20. Leggio L, Addolorato G, Abenavoli L Gasbarrini G. Wilson's disease: Clinical, genetic and pharmacological findings. Int J Immunopathol Pharmacol 2005; 18: 7-14.
21. Cognasse F, Chavarin P, Acquari S, et al. Differential downstream effects of ligation mediated by membrane or soluble CD40L and agnostic Ab: A study on purified human B cells. Int J Immunopathol Pharmacol 2005; 18: 65-74.
22. Somma P, Lo Muzio L, Mansueto G, et al. Squamous cell carcinoma of the lower lip: Fas/FasL expression, lymphocyte subtypes and outcome. Int J Immunopathol Pharmacol 2005; 18: 59-64.
23. Pannellini T, Iezzi M, Di Carlo E, et al. The expression of LEC/CCL16, a powerful inflammatory chemokine, is upregulated in ulcerative colitis. Int J Immunopathol Pharmacol 2004; 17: 171-80.
24. Falkensammer B, Fasser W, Scherer K, et al. Drug monitoring and viral response to lopinavir/ritonavir or saquinavir/ritonavir containing regimens in individuals infected with the Human Immunodeficiency Virus Type 1. Int J Immunopathol Pharmacol 2005; 18: 145-54.
25. Guidi L, Costanzo M, Ciarniello M, et al. Increased levels of NF-kB inhibitors (IkBα and IkBγ) in the intestinal mucosa of Crohn's disease patients during infliximab treatment. Int J Immunopathol Pharmacol 2005; 18: 155-64.
26. Sardella G, Accapezzato D, Di Roma A, et al. Integrin beta2-chain (CD18) over-expression on CD4+ T-cells and monocytes after ischemia/reperfusion in patients undergoing primary percutaneous revascularization. Int J Immunopathol Pharmacol 2004; 17: 165-70.
27. 3H]-5HT-releasing factor for mast cells and provokes cell aggregation. Immunology 1995; 86: 434-340.
28. Kaneider NC, Kaser A, Tilg H, Ricevuti G, Wiedermann CJ. CD40 ligand-dependent maturation of human monocyte-derived dendritic cells by activated platelets. Int J Immunopathol Pharmacol 2003; 16: 225-32.
29. Colotta F, Borre A, Ming-Wang J, et al. J Immunol 1992; 148: 760-5.
30. Yamaki K, Uchida H, Li X, et al. Effect of varying types of anti-arthritic drugs on Th1 and Th2 immune responses in mice. Int J Immunopathol Pharmacol 2005; 18: 133-44.
31. Goodman SB, Ma T, Genovese M, Lane Smith R. COX-2 selective inhibitors and bone. Int J Immunopathol Pharmacol 2003; 16: 201-6.
32. Gordon JR, Burd PR, Galli SJ. Mast cells as a source of multifunctional cytokines. Immunol Today 1990; 11: 458-64.
33. Furutani Y, Nomura H, Notake M, et al. Cloning and sequencing of the cDNA for human monocyte chemotactic and activating factor (MCAF). Bioch Biophys Res Commun 1989; 156: 249-55.
34. Ihle JN, Weinstein Y. Regulation of hematopoietic/lymphoid stem cell differentiation by interleukin-3. Adv Immunol 1989; 39: 1-39.
35. Licastro F, Chiappelli M, Ruscica M, Carnelli V, Corsi MM. Altered cytokine and acute phase response protein levels in the blood of children with Down's syndrome: Relationship with dementia of Alzheimer's type. Int J Immunopathol Pharmacol 2005; 18: 165-72.
36. Evanoff HL, Burdick MD, Moore SA, Kunkel SL, Streiter RM. A sensitive ELISA for the detection of human monocyte chemoattractant protein-1 (MCP-1). Immunol Invest 1992; 21: 39-45.
37. Austen Jr. WG, Kobzik L, Carroll MC, Hechtman HB, Moore FD Jr. The role of complement and natural antibody in intestinal ischemia-reperfusion injury. Int J Immunopathol Pharmacol 2003; 16: 1-8.
38. Hritz I, Molnár B, Tulassay Z, L Prónai. Proton pump inhibitor co-therapy normalizes the increased cell turnover of the gastric mucosa both in NSAID and selective Cox-2 users. Int J Immunopathol Pharmacol 2005; 18: 75-84.
39. Riccioni G, De Santis A, Cerasa V, et al. Atherosclerotic plaque formation and risk factors. Int J Immunopathol Pharmacol 2003; 16: 25-32.
40. Vojdani A, Pangborn JB, Vojdani E, Cooper EL. Infections, toxic chemicals and dietary peptides binding to lymphocyte receptors and tissue enzymes are major instigators of autoimmunity in autism. Int J Immunopathol Pharmacol 2003; 16: 189-200.
41. Mazzoccoli G, Grilli M, Carughi S, et al. Immune system alterations in lung cancer patients. Int J Immunopathol Pharmacol 2003; 16: 167-74.
42. Conti P, Pang X, Boucher W, et al. Impact of Rantes and MCP-1 chemokines on in vivo basophilic cell recruitment in rat skin injection model and their role in modifying the protein and mRNA levels for histidine decarboxylase. Blood 1997; 89: 4120-7.
43. Meurer R, Van Riper G, Feeney W, et al. Formation of eosinophilic and monocytic intradermal inflammatory sites in the dog by injection of human RANTES but not human monocyte chemoattractant protein I, human macrophage inflammatory protein Ia, or human interleukin-8. J Exp Med 1993; 178: 1913-21.
44. Shrivastava P, Singh SM, Singh N. Activation of tumor-associated macrophages by thymosin alpha 1. Int J Immunopathol Pharmacol 2004; 17: 39-47.
45. Liebler JM, Kunkel SL, Burdick MD, Standiford TJ, Rolfe MW, Streiter RM. Production of IL-8 and monocyte chemotactic peptide-1 by peripheral blood monocytes. J Immunol 1994; 152: 241-9.
46. Rollins BJ, Yoshimura T, Leonard EJ, Pober JS. Cytokine-activated human endothelial cells synthesise and secrete RANTES/JE. Am J Pathol 1990; 136: 1229-33.
47. Rovin BH, Yoshimura T, Lan T. Cytokine-induced production of monocyte chemotactic protein-1 by cultured human mesangeal cells. J Immunol 1993; 148: 2148-53.
48. Graves DT, Valente AJ. 1991. Monocyte chemotactic proteins from human tumor cells. Bioch Pharmacol 1992; 41: 333-41.
49. Weihrauch MR, Manzke O, Beyer M, et al. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: Potential for a prognostic factor. Cancer Res 2005; 65: 5516-9.
50. Kempuraj D, Donelan J, Frydas S, et al. Interleukin-28 and 29 (IL-28 and IL-29): New cytokines with anti-viral activities. Int J Immunopathol Pharmacol 2004; 17: 103-6.
51. Bellussi L, Marcucci F, Sensi LG, et al. Do tryptase, ECP and specific IgE measurement by nasal incubation increase the specific nasal provocation test sensitivity? Int J Immunopathol Pharmacol 2004; 17: 201-8.